Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Stock Information for Maplebear Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Maplebear Inc.

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.